<DOC>
	<DOCNO>NCT01723670</DOCNO>
	<brief_summary>To evaluate effect multiple dose regimen CHF 5074 administer per day 2 year potential biomarkers neurodegeneration subject mild cognitive impairment .</brief_summary>
	<brief_title>Evaluation Effects Multiple Dose Regimens CHF 5074 Potential Biomarkers Neurodegeneration Subjects With Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<criteria>One two ∆ê4 allele apolipoprotein E ( APOE ) gene . Diagnosis amnestic Mild Cognitive Impairment . MiniMental State Examination score high 24 screening . Diagnosis Alzheimer 's disease . Any medical condition could explain subject 's cognitive deficit . MRI scan evidence prespecified brain abnormality . History stroke . Vitamin B12 folate deficiency . Skin cancer cancer actively treat . Diagnosis schizophrenia recurrent mood disorder . Abnormal kidney function . Concomitant use study prohibitive medication .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>